Your web browser is out of date.

For your security and improved experience online, please update your browser.
Update your browser

Diabetes on the Net is intended for healthcare professionals

back to main site

Back

Resources

Novo Nordisk Limited

Go to website

on-demand video

Play Video

Can an oral GLP-1RA help your people living with type 2 diabetes? Exploring the person centered consultation

This promotional video presentation was originally broadcast on 18 November 2021. Please note that the speaker is not able to answer questions from attendees watching the video on-demand.

This promotional symposium has been developed, organised, and funded by Novo Nordisk. Novo Nordisk products will be discussed during this symposium.

Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored for training purposes.
This content is for UK Healthcare Professionals only
Click here to access Rybelsus®▼ (semaglutide tablets) prescribing information

Resources

RYBELSUS® HCP Practical Guide
Patients prescribed Rybelsus® leaflet
Rybelsus® Healthcare Professional Leaflet

Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored for training purposes.

Company profile

At Novo Nordisk, our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. Novo Nordisk is a leading global healthcare company, founded in 1923 and our heritage has given us experience and capabilities that enable us to expand access to our medicines and work to prevent and ultimately cure disease by pioneering scientific breakthroughs. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Every day, millions of people all over the world rely on our products. For more information visit www.novonordisk.co.uk

Job code: UK22GLP00010  |  Date of preparation: February 2022

get the latest news

subscribe now

© Copyright OmniaMed Communications. All Rights Reserved

Practical experiences from running an adeno-associated virus gene therapy trials: The Principal Investigator’s perspective

XX September 2020

Complete the registration form

XX Month 2020

Complete the registration form

We use cookies to ensure that we give you the best experience on our website. Some may have been set already. If you continue without changing your settings, we’ll assume that you are happy to receive all cookies on this website. Read about how we use cookies. If you have any concerns about this, please click here to find out more.

Confirm
* Mandatory Field
Your data is being collected by OmniaMed Communications on behalf of Novo Nordisk solely for the purpose of processing your registration. Your details will not be shared with any parties other than OmniaMed Communications and Novo Nordisk.